Predictors of Bone Metastases at <sup>68</sup>Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer (HSPC) Patients with Early Biochemical Recurrence or Persistence
Prostate-specific-membrane-antigen/positron-emission-tomography (PSMA-PET) can accurately detect disease localizations in prostate cancer (PCa) patients with early biochemical recurrence/persistence (BCR/BCP), allowing for more personalized image-guided treatments in oligometastatic patients with ma...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/12/6/1309 |
| _version_ | 1797488361323102208 |
|---|---|
| author | Guido Rovera Serena Grimaldi Sara Dall’Armellina Roberto Passera Marco Oderda Giuseppe Carlo Iorio Alessia Guarneri Paolo Gontero Umberto Ricardi Désirée Deandreis |
| author_facet | Guido Rovera Serena Grimaldi Sara Dall’Armellina Roberto Passera Marco Oderda Giuseppe Carlo Iorio Alessia Guarneri Paolo Gontero Umberto Ricardi Désirée Deandreis |
| author_sort | Guido Rovera |
| collection | DOAJ |
| description | Prostate-specific-membrane-antigen/positron-emission-tomography (PSMA-PET) can accurately detect disease localizations in prostate cancer (PCa) patients with early biochemical recurrence/persistence (BCR/BCP), allowing for more personalized image-guided treatments in oligometastatic patients with major impact in the case of bone metastases (BM). Therefore, this study aimed to identify predictors of BM at PSMA-PET in early-BCR/BCP hormone-sensitive PCa (HSPC) patients, previously treated with radical intent (radiotherapy or radical prostatectomy ± salvage-radiotherapy (SRT)). A retrospective analysis was performed on 443 <sup>68</sup>Ga-PSMA-11-PET/CT scans. The cohort median PSA at PET-scan was 0.60 (IQR: 0.38–1.04) ng/mL. PSMA-PET detection rate was 42.0% (186/443), and distant lesions (M1a/b/c) were found in 17.6% (78/443) of cases. BM (M1b) were present in 9.9% (44/443) of cases, with 70.5% (31/44) showing oligometastatic spread (≤3 PSMA-positive lesions). In the multivariate binary logistic regression model (accuracy: 71.2%, Nagelkerke-R<sup>2</sup>: 13%), T stage ≥ 3a (OR: 2.52; 95% CI: 1.13–5.60; <i>p</i> = 0.024), clinical setting (previous SRT vs. first-time BCR OR: 2.90; 95% CI: 1.32–6.35; <i>p</i> = 0.008), and PSAdt (OR: 0.93; 95% CI: 0.88–0.99; <i>p</i> = 0.026) were proven to be significant predictors of bone metastases, with a 7% risk increment for each single-unit decrement of PSAdt. These predictors could be used to further refine the indication for PSMA-PET in early BCR/BCP HSPC patients, leading to higher detection rates of bone disease and more personalized treatments. |
| first_indexed | 2024-03-10T00:01:01Z |
| format | Article |
| id | doaj.art-1eff3bb8acaa42a2a1ae7c1d24e7e53d |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-10T00:01:01Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-1eff3bb8acaa42a2a1ae7c1d24e7e53d2023-11-23T16:16:01ZengMDPI AGDiagnostics2075-44182022-05-01126130910.3390/diagnostics12061309Predictors of Bone Metastases at <sup>68</sup>Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer (HSPC) Patients with Early Biochemical Recurrence or PersistenceGuido Rovera0Serena Grimaldi1Sara Dall’Armellina2Roberto Passera3Marco Oderda4Giuseppe Carlo Iorio5Alessia Guarneri6Paolo Gontero7Umberto Ricardi8Désirée Deandreis9Nuclear Medicine, Department of Medical Sciences, AOU Città Della Salute e Della Scienza di Torino, University of Turin, 10126 Turin, ItalyNuclear Medicine, Department of Medical Sciences, AOU Città Della Salute e Della Scienza di Torino, University of Turin, 10126 Turin, ItalyNuclear Medicine, Department of Medical Sciences, AOU Città Della Salute e Della Scienza di Torino, University of Turin, 10126 Turin, ItalyNuclear Medicine, Department of Medical Sciences, AOU Città Della Salute e Della Scienza di Torino, University of Turin, 10126 Turin, ItalyUrology, Department of Surgical Sciences, AOU Città Della Salute e Della Scienza di Torino, University of Turin, 10126 Turin, ItalyDepartment of Oncology, University of Torino, 10125 Torino, ItalyDepartment of Oncology, University of Torino, 10125 Torino, ItalyUrology, Department of Surgical Sciences, AOU Città Della Salute e Della Scienza di Torino, University of Turin, 10126 Turin, ItalyDepartment of Oncology, University of Torino, 10125 Torino, ItalyNuclear Medicine, Department of Medical Sciences, AOU Città Della Salute e Della Scienza di Torino, University of Turin, 10126 Turin, ItalyProstate-specific-membrane-antigen/positron-emission-tomography (PSMA-PET) can accurately detect disease localizations in prostate cancer (PCa) patients with early biochemical recurrence/persistence (BCR/BCP), allowing for more personalized image-guided treatments in oligometastatic patients with major impact in the case of bone metastases (BM). Therefore, this study aimed to identify predictors of BM at PSMA-PET in early-BCR/BCP hormone-sensitive PCa (HSPC) patients, previously treated with radical intent (radiotherapy or radical prostatectomy ± salvage-radiotherapy (SRT)). A retrospective analysis was performed on 443 <sup>68</sup>Ga-PSMA-11-PET/CT scans. The cohort median PSA at PET-scan was 0.60 (IQR: 0.38–1.04) ng/mL. PSMA-PET detection rate was 42.0% (186/443), and distant lesions (M1a/b/c) were found in 17.6% (78/443) of cases. BM (M1b) were present in 9.9% (44/443) of cases, with 70.5% (31/44) showing oligometastatic spread (≤3 PSMA-positive lesions). In the multivariate binary logistic regression model (accuracy: 71.2%, Nagelkerke-R<sup>2</sup>: 13%), T stage ≥ 3a (OR: 2.52; 95% CI: 1.13–5.60; <i>p</i> = 0.024), clinical setting (previous SRT vs. first-time BCR OR: 2.90; 95% CI: 1.32–6.35; <i>p</i> = 0.008), and PSAdt (OR: 0.93; 95% CI: 0.88–0.99; <i>p</i> = 0.026) were proven to be significant predictors of bone metastases, with a 7% risk increment for each single-unit decrement of PSAdt. These predictors could be used to further refine the indication for PSMA-PET in early BCR/BCP HSPC patients, leading to higher detection rates of bone disease and more personalized treatments.https://www.mdpi.com/2075-4418/12/6/1309prostatic neoplasmhormone-sensitive prostate cancerPSMA PETbone diseasepredictive model |
| spellingShingle | Guido Rovera Serena Grimaldi Sara Dall’Armellina Roberto Passera Marco Oderda Giuseppe Carlo Iorio Alessia Guarneri Paolo Gontero Umberto Ricardi Désirée Deandreis Predictors of Bone Metastases at <sup>68</sup>Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer (HSPC) Patients with Early Biochemical Recurrence or Persistence Diagnostics prostatic neoplasm hormone-sensitive prostate cancer PSMA PET bone disease predictive model |
| title | Predictors of Bone Metastases at <sup>68</sup>Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer (HSPC) Patients with Early Biochemical Recurrence or Persistence |
| title_full | Predictors of Bone Metastases at <sup>68</sup>Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer (HSPC) Patients with Early Biochemical Recurrence or Persistence |
| title_fullStr | Predictors of Bone Metastases at <sup>68</sup>Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer (HSPC) Patients with Early Biochemical Recurrence or Persistence |
| title_full_unstemmed | Predictors of Bone Metastases at <sup>68</sup>Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer (HSPC) Patients with Early Biochemical Recurrence or Persistence |
| title_short | Predictors of Bone Metastases at <sup>68</sup>Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer (HSPC) Patients with Early Biochemical Recurrence or Persistence |
| title_sort | predictors of bone metastases at sup 68 sup ga psma 11 pet ct in hormone sensitive prostate cancer hspc patients with early biochemical recurrence or persistence |
| topic | prostatic neoplasm hormone-sensitive prostate cancer PSMA PET bone disease predictive model |
| url | https://www.mdpi.com/2075-4418/12/6/1309 |
| work_keys_str_mv | AT guidorovera predictorsofbonemetastasesatsup68supgapsma11petctinhormonesensitiveprostatecancerhspcpatientswithearlybiochemicalrecurrenceorpersistence AT serenagrimaldi predictorsofbonemetastasesatsup68supgapsma11petctinhormonesensitiveprostatecancerhspcpatientswithearlybiochemicalrecurrenceorpersistence AT saradallarmellina predictorsofbonemetastasesatsup68supgapsma11petctinhormonesensitiveprostatecancerhspcpatientswithearlybiochemicalrecurrenceorpersistence AT robertopassera predictorsofbonemetastasesatsup68supgapsma11petctinhormonesensitiveprostatecancerhspcpatientswithearlybiochemicalrecurrenceorpersistence AT marcooderda predictorsofbonemetastasesatsup68supgapsma11petctinhormonesensitiveprostatecancerhspcpatientswithearlybiochemicalrecurrenceorpersistence AT giuseppecarloiorio predictorsofbonemetastasesatsup68supgapsma11petctinhormonesensitiveprostatecancerhspcpatientswithearlybiochemicalrecurrenceorpersistence AT alessiaguarneri predictorsofbonemetastasesatsup68supgapsma11petctinhormonesensitiveprostatecancerhspcpatientswithearlybiochemicalrecurrenceorpersistence AT paologontero predictorsofbonemetastasesatsup68supgapsma11petctinhormonesensitiveprostatecancerhspcpatientswithearlybiochemicalrecurrenceorpersistence AT umbertoricardi predictorsofbonemetastasesatsup68supgapsma11petctinhormonesensitiveprostatecancerhspcpatientswithearlybiochemicalrecurrenceorpersistence AT desireedeandreis predictorsofbonemetastasesatsup68supgapsma11petctinhormonesensitiveprostatecancerhspcpatientswithearlybiochemicalrecurrenceorpersistence |